An observational study in Head and Neck Cancer, sponsored by Royal Marsden NHS Foundation Trust. Active, not recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Royal Marsden NHS Foundation Trust · Observational
Among 18 studies in Head and Neck Neoplasms by Royal Marsden NHS Foundation Trust — 6 open to participants now, 7 under way, none of them phase 3. Head and Neck Neoplasms · Royal Marsden NHS Foundation Trust.
Among the 18 studies in Head and Neck Neoplasms by Royal Marsden NHS Foundation Trust, this one is the 2nd largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2026, is one of 12 observational ones, and was the 18th registered.
2,713 studies on the registry are indexed under Head and Neck Neoplasms; 596 are open to participants now.
Browse Head and Neck Neoplasms studies →6 of the 18 studies in Head and Neck Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 1 country. Recruiting first, the newest first:
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 19+
By country, each count listing its studies:
Of the 453 Head and Neck Neoplasms studies recruiting now, 345 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 21 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2
First in 1997; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125,000 is above the median of 100 across 504 observational studies indexed under Head and Neck Neoplasms.
Median enrollment 73 across the 5 interventional studies, 208 across the 12 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Royal Marsden NHS Foundation Trust is the lead sponsor of 274 studies on the registry; 53 are open to participants now.
1 of the studies in Head and Neck Neoplasms by Royal Marsden NHS Foundation Trust that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05933889Royal Marsden NHS Foundation TrustSingle and Combined Modality Trans-Oral Robotic Surgery in Early Oropharyngeal Cancer | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Head and Neck Neoplasms by Royal Marsden NHS Foundation Trust, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to get a better understanding which patient characteristics, available in routinely collected data, are associated with the probability that patients referred because of suspected head-and-neck cancer will receive a head-and-neck cancer diagnosis.
Participants will not be recruited specifically for this study. Instead, we will be using routinely-collected national electronic health records linked at patient level, including the National Cancer Waiting Times Monitoring Data (CWT), the National Cancer Registration Data set (NCRD), the Radiotherapy Data set (RTDS), the Systemic Anti-Cancer Therapy Data set (SACT) and the Hospital Episode Statistics.
The main questions it aims to answer are:
All patients referred for suspected head-and-neck cancer (according to Cancer Waiting Times [CWT] data) or diagnosed with head-and-neck cancer (according to National Cancer Registration data) during the study period (01 April 2013 to most recent available, with CWT data available from 01 April 2018).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients referred for suspected head-and-neck cancer according to the Cancer Waiting Times dataset (01 April 2018 to most recent available) will be included. The cohort definition is based on International Classification of Diseases 10th Edition (ICD-10) codes, defining site-specific cancers in oral cavity, tongue, pharynx, and larynx (C00-C14; C30-C32; C43.0 - C43.4; C44.3; C44.4; C73.0; C76.0; C77.0).
All patients with a confirmed head-and-neck cancer diagnosis between 1 January 2018 and 31 December 2024 according to the National Cancer Registry will be included. The cohort definition is based on International Classification of Diseases 10th Edition (ICD-10) codes, defining site-specific cancers in oral cavity, tongue, pharynx, and larynx (C00-C14; C30-C32; C43.0 - C43.4; C44.3; C44.4; C73.0; C76.0; C77.0).
To describe the patients who are referred with a suspected head-and-neck cancer diagnosis and those who have a confirmed diagnosis
Time frame: Point of diagnosis, on average 62 days
To create a typology of the diagnostic pathway across the country (e.g., comparing 21 regions reflecting the Cancer Alliances)
Time frame: Point of diagnosis, on average 62 days
To explore differences among the 21 NHS Cancer Alliances in the referral rates of patients with suspected head-and-neck cancer and the number of referred patients in whom a cancer can be diagnosed.
Time frame: Point of diagnosis, on average 62 days
To develop a prognostic model that can predict the probability that referred patients will receive a head-and-neck cancer diagnosis.
Time frame: Point of diagnosis, on average 62 days
To evaluate the value of HES, NCRD, RTDS and SACT to monitor referral pathways for patients with suspected head-and-neck cancer.
Time frame: Point of diagnosis, on average 62 days
To develop a health economic model of the diagnostic and treatment pathway of referrals for suspected head-and-neck cancer
Time frame: Through study completion, an average of 5 years
To assess hospital care costs across the diagnostic and treatment pathways for HN cancer.
Time frame: Through study completion, an average of 5 years
Plan to share: No — The linked data sets will be stored and accessed within the NHS England Secure Data Environment (SDE) with access limited to approved members of the research team. Access to the data is governed and controlled by NHS England.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Aug 2028, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust →